公开(公告)号：US09849146B2

公开(公告)日：2017-12-26

申请号：US14126342

申请日：2012-06-13

Applicant: Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut M. Hanauske-Abel

Inventor： Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut M. Hanauske-Abel

IPC: A61K31/4412 ,  A61K31/7105 ,  A61K31/7064 ,  A61K31/4375 ,  A61K45/06 ,  A61K31/4418 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/7036 ,  A61K31/7048

CPC classification number: A61K31/7105 ,  A61K31/4375 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7064 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.

公开(公告)号：US20170319612A9

公开(公告)日：2017-11-09

申请号：US14126342

申请日：2012-06-13

Applicant: Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut M. Hanauske-Abel

Inventor： Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut M. Hanauske-Abel

IPC: A61K31/7105 ,  A61K31/4418 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/4412 ,  A61K31/5025 ,  A61K45/06 ,  A61K31/7064 ,  A61K31/4375 ,  A61K31/502

CPC classification number: A61K31/7105 ,  A61K31/4375 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7064 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.

公开(公告)号：US20140206637A1

公开(公告)日：2014-07-24

申请号：US14126342

申请日：2012-06-13

Applicant: Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut M. Hanauske-Abel

Inventor： Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut M. Hanauske-Abel

IPC: A61K31/7105 ,  A61K31/704 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/4412 ,  A61K31/7064

CPC classification number: A61K31/7105 ,  A61K31/4375 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7064 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.

Abstract translation: 提供了用于治疗NAD的方法，包括对患有NMD的NMD抑制剂和无义抑制剂的患者施用，由此NMD敏感性mRNA的降解降低，并且在错放的无义​​密码子处的翻译终止被阻断。

公开(公告)号：US20120225093A1

公开(公告)日：2012-09-06

申请号：US13271190

申请日：2011-10-11

Applicant: Michael B. Mathews ,  Hartmut M. Hanauske-Abel ,  Tsafi Pe'ery ,  Mainul Hoque ,  Paul Palumbo ,  Deepti Saxena ,  Darlene D'Alliessi-Gandolfi ,  Myung-Hee Park

Inventor： Michael B. Mathews ,  Hartmut M. Hanauske-Abel ,  Tsafi Pe'ery ,  Mainul Hoque ,  Paul Palumbo ,  Deepti Saxena ,  Darlene D'Alliessi-Gandolfi ,  Myung-Hee Park

IPC: A61K31/4412 ,  A61K31/4418 ,  A61P37/04 ,  C40B30/04 ,  A61P31/18 ,  C12Q1/70 ,  A61K39/21

CPC classification number: C12Q1/18 ,  A61K31/4412 ,  A61K31/4418 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/515 ,  C12N2740/16034 ,  G01N2333/5428 ,  G01N2333/57 ,  A61K2300/00

Abstract: The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection.

Abstract translation: 本发明涉及治疗，抑制或控制HIV感染的组合物和方法。

公开(公告)号：US20140329700A1

公开(公告)日：2014-11-06

申请号：US14240514

申请日：2012-08-23

Applicant: Bin Tian ,  Wenting Luo ,  Zhe Ji ,  Mainul Hoque

Inventor： Bin Tian ,  Wenting Luo ,  Zhe Ji ,  Mainul Hoque

IPC: C12Q1/68

CPC classification number: C12Q1/6876 ,  C12Q1/6806 ,  C12Q1/6813 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/166 ,  C12Q2525/173

Abstract: The invention relates to compositions and methods to isolate nucleic acids, and the identification of polyadenylation sites in a gene of interest. In one aspect, the invention provides an oligonucleotide comprising at least one nucleic acid and an affinity moiety, wherein said nucleic acid is 30-60 nucleotides in length and said nucleic acid comprises 1-25 uracil and 5-50 thymine nucleotides.

Abstract translation: 本发明涉及分离核酸的组合物和方法，以及目的基因中多聚腺苷酸化位点的鉴定。 一方面，本发明提供了包含至少一个核酸和亲和部分的寡核苷酸，其中所述核酸的长度为30-60个核苷酸，所述核酸包含1-25个尿嘧啶和5-50个胸腺嘧啶核苷酸。

公开(公告)号：US20110039911A1

公开(公告)日：2011-02-17

申请号：US12840270

申请日：2010-07-20

Applicant: Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut Martin Hanauske-Abel

Inventor： Tsafi Pe'ery ,  Michael B. Mathews ,  Mainul Hoque ,  Hartmut Martin Hanauske-Abel

IPC: A61K31/44 ,  A61K31/426 ,  A61P25/28 ,  A61P35/04 ,  A61P9/00 ,  A61P3/00 ,  C12Q1/68

CPC classification number: A61K31/713 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4418

Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.

Abstract translation: 提供了用于治疗NAD的方法，包括向患有NAD的患者施用含有eIF5A抑制剂化合物的组合物，其量为有效预防eIF5A的细胞内嗜酸性化，由此NMD敏感mRNA的基因表达增加。

公开(公告)号：US20120095058A1

公开(公告)日：2012-04-19

申请号：US10581658

申请日：2004-12-01

Applicant: H., M. Hanauske-Abel ,  Paul Palumbo ,  B., M. Cracchiolo ,  Myung-Hee Park ,  Edith Wolff ,  Axel-Rainer Hanauske ,  Michael B. Mathews ,  Deepti Saxena ,  Mainul Hoque

Inventor： H., M. Hanauske-Abel ,  Paul Palumbo ,  B., M. Cracchiolo ,  Myung-Hee Park ,  Edith Wolff ,  Axel-Rainer Hanauske ,  Michael B. Mathews ,  Deepti Saxena ,  Mainul Hoque

IPC: A61K31/4418 ,  A61K31/4439 ,  A61K31/4412 ,  A61P31/18 ,  A61P31/14 ,  C12N5/071 ,  A61K31/426 ,  A61P31/12

CPC classification number: A61K31/4412

Abstract: The present invention discloses compounds and pharmaceutical compositions which are highly effective at inhibiting the accumulation of spliced and unspliced viral transcripts and their utilization for viral protein synthesis at cellular ribosomes, and at inhibiting the formation of the hypusine residue in cellular eIF-5A precursor proteins, the cellular cofactors that render spliced and unspliced viral transcripts translatable at the ribosomes of infectled cells. The invention further relates to methods of using such compounds and pharmaceutical compositions therefrom for inhibiting or preventing viral protein synthesis. Such inhibition cause a dose-dependent release from the virally induced arrest of the otherwise genetically preprogrammed apoptosis of virally infected cells, and in consequence, triggers their apoptotic ablation and the eradication of the chronic infection-mediating provirus integrated into their genome.

Abstract translation: 本发明公开了在细胞核糖体上抑制拼接和未被剪接的病毒转录物的积累及其在病毒蛋白质合成中的用途以及抑制细胞eIF-5A前体蛋白质中的hypusine残基的形成的高度有效的化合物和药物组合物， 使受剪接和未被剪接的病毒转录物在感染细胞核糖体中可翻译的细胞辅因子。 本发明还涉及使用这些化合物及其药物组合物来抑制或预防病毒蛋白质合成的方法。 这种抑制引起药物诱导的阻止病毒感染细胞的遗传预编程性细胞凋亡的剂量依赖性释放，因此触发其凋亡消融并消除整合到其基因组中的慢性感染介导性原病毒。